Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
18.34 USD | -1.74% | -7.30% | +203.32% |
Financials (USD)
Sales 2024 * | 2.14M | Sales 2025 * | - | Capitalization | 726M |
---|---|---|---|---|---|
Net income 2024 * | -66M | Net income 2025 * | -93M | EV / Sales 2024 * | 214 x |
Net cash position 2024 * | 267M | Net cash position 2025 * | 320M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-10
x | P/E ratio 2025 * |
-8.17
x | Employees | 50 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.5% |
Latest transcript on Longboard Pharmaceuticals, Inc.
1 day | -1.61% | ||
1 week | -8.16% | ||
Current month | -14.93% | ||
1 month | -14.65% | ||
3 months | -18.30% | ||
6 months | +392.39% | ||
Current year | +200.50% |
Managers | Title | Age | Since |
---|---|---|---|
Kevin Lind
CEO | Chief Executive Officer | 47 | 20-01-02 |
Brandi Roberts
DFI | Director of Finance/CFO | 50 | 20-12-31 |
Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Sekhri
CHM | Chairman | 66 | 20-11-30 |
Director/Board Member | 68 | 20-11-30 | |
Vincent Aurentz
BRD | Director/Board Member | 56 | 20-01-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.41% | 4 M€ | -5.15% | - | |
0.00% | 34 M€ | +4.49% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-29 | 18.29 | -1.98% | 212 491 |
24-05-28 | 18.66 | -0.74% | 298,179 |
24-05-24 | 18.8 | -0.74% | 167,002 |
24-05-23 | 18.94 | -4.00% | 250,374 |
24-05-22 | 19.73 | -3.28% | 243,271 |
Delayed Quote Nasdaq, May 29, 2024 at 10:10 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+200.50% | 726M | |
+9.43% | 115B | |
+9.90% | 105B | |
-12.75% | 22.71B | |
+2.68% | 21.83B | |
-10.81% | 18.18B | |
-41.92% | 16.52B | |
-16.32% | 16.01B | |
+1.42% | 14.14B | |
+18.23% | 10.71B |
- Stock Market
- Equities
- LBPH Stock